Oxoazepine derivatives

Abstract

This invention relates to novel oxoazepine derivatives of Formula (I),R.sup.1 R.sup.2 NCOCH.sub.2 N(R.sup.3)COR.sup.4 (I)to processes for their preparation, to pharmaceutical compositions containing them and to their use in medicine. More particularly, it relates to compounds which exhibit agonist activity for CCK-A receptors thereby enabling them to modulate the hormones gastrin and cholecystokinin (CCK) in mammals.

Claims

1. A compound of formula (I)

R.sup.1 is C.sub.3-6 alkyl, C.sub.3-6 cycloalkyl, C.sub.3-6 alkenyl, phenyl, --(CH.sub.2).sub.p CN or --(CH.sub.2).sub.p COO(C.sub.1-4 alkyl) and

R.sup.2 is C.sub.3-6 cycloalkyl, C.sub.3-6 alkenyl, benzyl, phenyl, or phenyl mono- or disubstituted independently with C.sub.1-3 alkyl, cyano, hydroxy, dimethylamino, --O(C.sub.1-4 alkyl), --O(CII.sub.2 C.sub.6 II.sub.5), --NH(C.sub.1-4 alkyl), --COOC(C.sub.1-4 alkyl), --N(C.sub.1-4 alkyl).sub.2 pyrrolidino, morpholino, halogen, or C.sub.1-3 alkyl substituted by one or more fluorine atoms, or R.sup.1 is C.sub.1-2 alkyl and R.sup.2 is phenyl substituted at the 2- or 4-position with chloro, methyl, methoxy, or methoxycarbonyl;

R.sup.4 is a group of formula (III) ##STR13## where n is 0, 1, 2 or 3; p is the integer 0 or 1;

q is the integer 0 or 1;

r is the integer 0 or 1, provided that when q is 0 then r is 0;

R.sup.9 is hydrogen or C.sub.1-6 alkyl;

R.sup.5 is C.sub.1-6 alkyl,C.sub.3-6 cycloalkyl, phenyl, phenyl mono-, di or trisubstituted independently with C.sub.1-4 alkyl, hydroxy, C.sub.1-6 alkoxy, halogen, amino, mono- or di(C.sub.1-6 alkyl)amino, nitro, carboxy, --COO(C.sub.1-4 alkyl), carboxyC.sub.1-6 alkoxy, carboxyC.sub.1-4 alkyl, carboxymethylthio, heteroaryl, mono- or di(C.sub.1-6 alkyl)aminoalkyl, or trifluoromethyl, trifluoromethoxy, C.sub.1-4 alkylthio, --SO.sub.v (C.sub.1-4 alkyl), --SO.sub.V NH(C.sub.1-4 alkyl), --SO.sub.v CF.sub.3 or --SO.sub.v C.sub.6 H.sub.5, --(CH.sub.2).sub.v,NO.sub.2, --(CH.sub.2).sub.v CN, --(CH.sub.2).sub.v COOH, --(CH.sub.2).sub.v COO(C.sub.1-4 alkyl), --(CH.sub.2).sub.v SCH.sub.3, --(CH.sub.2).sub.v SOCH.sub.3, --(CH.sub.2).sub.v SO.sub.3 H, CH(C.sub.1-3 alkyl)SO.sub.3 H, CH(C.sub.1-3 alkyl)CO.sub.2 H,

(CH.sub.2).sub.v SO.sub.2 CH.sub.3, --(CH.sub.2).sub.v CONH.sub.2, --SCH.sub.2 COOH, --CONH(SO.sub.2 CH.sub.3), --CONH(SO.sub.2 CF.sub.3)--(CH.sub.2).sub.v N(C.sub.1-4 alkyl.sub.2, --(CH.sub.2).sub.v NH(SO.sub.2 CF.sub.3) --CH.sub.2).sub.v N(SO.sub.2 CF.sub.3)C.sub.1-4 alkyl), --(CH.sub.2).sub.v SO.sub.2 N(HCOC.sub.1-4 alkyl)-(CH.sub.2).sub.v SO.sub.2 N(C.sub.1-4 alkyl),CO(C.sub.1-4 alkyl), --(CH.sub.2).sub.v CONHSO.sub.2 (C.sub.1-4 alkyl), --(CH.sub.2).sub.v CON(C.sub.1-4 alkyl)SO.sub.2 (C.sub.1-4 alkyl), --(CH.sub.2).sub.v NHR.sup.10 or (CH.sub.2).sub.v OR.sup.11 substituents; heteroaryl (provided when R.sup.5 is oxadiazole then R.sup.9 is not hydrogen), heteroaryl substituted with halogen, C.sub.1-6 alkyl, hydroxy, nitro, cyano, carboxy, C.sub.1-6 alkoxy, benzoxy, --COO(C.sub.1-4 alkyl), amino, mono- or di(C.sub.1-6 alkyl)amino, phenyl or benzyl substituents; naphthyl; bicycloheteroaryl or bicycloheteroaryl N-substituted independently with hydroxy, carboxyalkyl, phenyl, heteroaryl, C.sub.1-4 alkoxy or cyano substituents, further provided when n is 1, p is 0, q is 0 and r is 0 then heteroaryl, substituted heteroaryl, bicycloheteroaryl and substituted bicycloheteroaryl are bound at the 3 position, still further provided that when n is 0, p is 1, q is 1 and r is 0 then heteraryl, substituted heteroaryl, bicycloheteroaryl and substituted bicycloheteroaryl are bound at the 2 position;

R.sup.10 is hydrogen acetyl, C.sub.1-4 alkyl, SO.sub.3 H, --SO.sub.2 CH.sub.3, --SO.sub.2 CF.sub.3, --SO.sub.2 C.sub.6 H.sub.5, C.sub.1-4 alkoxycarbonyl

R.sup.11 is hydrogen, C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl, --CH.sub.2 C.sub.6 H.sub.5, --CH.sub.2 COOH, --CH.sub.2 CONH.sub.2, --CH.sub.2 CONH(C.sub.1-4 alkyl), --CH.sub.2 CON(C.sub.1-4 alkyl).sub.2 or ##STR14## v 0, 1 or 2; c is zero or 1

R.sup.3 and R.sup.6 together form a linking chain ##STR15## wherein the group Z is linked to the rest of the molecule at the carbon atom substituted by the group R.sup.9 and

wherein Z is CH.sub.2, C(CH.sub.3).sub.2, --C(CH.sub.3) or CO, Y is a group selected from S, SO, SO.sub.2, CO or CH.sub.2, R.sup.12, R.sup.13, R.sup.14 and R.sup.15 each represent hydrogen, or R.sup.13 and R.sup.14 together form a double bond and R.sup.12 and R.sup.15 are both hydrogen.

3. A compound according to claim 1 wherein

R.sup.1 is isopropyl;

R.sup.2 is phenyl or methoxyphenyl; and

R.sup.9 is H.

4. A compound according to claim 1 wherein

R.sup.1 is isopropyl;

R.sup.2 is phenyl;

R.sup.9 is H;

n is 0, p is 1, q is 1, r is 0 or 1;

Z is CH.sub.2 or CO.

5. A compound according to claim 1 wherein

R.sup.1 is isopropyl;

R.sup.2 is methoxyphenyl;

R.sup.9 is H;

n is 1, p is 0, q is 0, r is 0;

Z is CO.

7. A method for the treatment of conditions where modification of the effect of CCK and/or gastrin is of therapeutic benefit, comprising administering to the patient and therapeutically effective amount of a compound as claimed in claim 1 or a pharmaceutically acceptable salt thereof.

8. A pharmaceutical composition comprising a compound as claimed in claim 1 or a pharmaceutically acceptable salt thereof together with one or more pharmaceutically acceptable carriers.